Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BGIP’s specialises in the development, production, marketing and sales of products for proteomic and genomic research
Subscribe to our email newsletter
Merck KGaA’s wholly-owned subsidiary in India, Merck Specialities, has acquired Bangalore Genei (BGIP) from the Sanmar Group.
BGIP is located in Bangalore and specialises in the development, production, marketing and sales of products for proteomic and genomic research. With more than 100 employees, the company generated total revenues of INR202m (E3 million) in fiscal year 2008/09.
Christina Shasserre, global head of bioscience business at Merck, said: “BGIP’s product portfolio comprises a wide range of bioscience products, which are tailored to the needs of the domestic market in India.”
Germany-based Merck is a pharmaceutical and chemical company with total revenues of E7.6 billion in 2008. Merck’s operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and free shareholders own the remaining approximately 30%.